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Abstract: Free circulating DNA, which is thought to be derived from the primary tumour, can be detected in the blood of 
patients with cancer. Detection of genetic and epigenetic alteration in this tumour DNA offers a potential source of develop-
ment of prognostic and predictive biomarkers for cancer. One such change is DNA methylation of the promotor region of 
tumour suppressor genes. This causes down regulation of tumour suppressor gene expression, a frequent event in carcino-
genesis. Hypermethylation of the promotor region of a number of genes has been detected in many tumour types and more 
recently these changes have been detected in circulating tumour DNA. This review will summarise the literature detailing 
DNA methylation in circulating tumour DNA and discuss some of the current controversies and technical challenges facing 
its use as a potential biomarker for cancer.
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Introduction
There is currently great interest in the development of tumour biomarkers to aid the management of 
cancer. “A biomarker is a characteristic that is objectively measured and evaluated as an indicator of 
normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic interven-
tion” (National Institute of Health Biomarkers working party, 2001).
Tumour biomarkers in current clinical use are generally proteins secreted by the tumour such as 
CA-125 (Rustin et al. 1996) and PSA (prostate speciﬁ  c antigen) (Kelly et al. 1993), or cell surface 
receptors that can predict response to speciﬁ  c targeted treatments, such as HER2 overexpression in 
breast cancer which is predictive of response to targeted inhibition of HER2 with trastuzumab (Baselga 
et al. 1996). However, similar tumour markers are not available for all cancers and many of the avail-
able markers have shortcomings in terms of sensitivity and speciﬁ  city. 
The development of robust blood-based biomarkers that accurately reﬂ  ect the host tumour is an 
emerging ﬁ  eld. Whilst DNA alterations can be assessed within a primary tumour sample, a less inva-
sive and ‘patient friendly’ option is detection of these changes within patients’ blood. Biomarkers 
which require a tumour sample can impose constraints on clinical utility particularly in disease settings 
where obtaining tumour tissue prior to treatment is problematic (e.g. pancreatic, CNS tumours). Often 
tumours are inaccessible to biopsy and repeated biopsies of a tumour to assess changes in biomarkers 
are rarely practical or acceptable to patients. The correlation of alterations in tumour DNA with 
circulating tumour DNA would allow potential development of clinically relevant biomarker blood 
tests for early detection of cancer, prediction of a likely treatment effect and assessment of tumour 
response to therapy.
DNA-based biomarkers are an attractive option compared to RNA and protein-based biomarkers. 
DNA is inherently stable compared to RNA which is rapidly degraded at room temperature. Thus it is 308
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more feasible to isolate and analyse DNA and 
extraction can be performed on stored and archival 
samples.
Advances in molecular biology have lead to 
a rapid growth in the understanding of genetic 
and epigenetic change in cancer. Modern molec-
ular detection methods such as polymerase chain 
reaction (PCR)-based assays can detect and 
quantify small amounts of nucleic acids and 
these technologies offer a potentially low cost, 
high throughput and sensitive method for the 
evaluation of genetic change in cancer. Recently 
the role of methylation in altering gene expres-
sion has been described and this has been 
detected in both tumour and circulating tumour 
DNA. This review will discuss some of the 
technical challenges related to the study of 
circulating tumour DNA, outline the role of 
DNA methylation in cancer and summarise the 
current evidence supporting the potential use of 
DNA methylation in circulating tumour DNA 
as a potential biomarker for cancer.
Circulating Tumour DNA
Small amounts of free DNA (approximately 1ng 
of soluble DNA/ml) are found circulating in the 
plasma of healthy individuals, (Shapiro et al. 
1983). Increased levels have been reported in the 
serum or plasma of patients with a variety of 
illnesses including autoimmune disease, chronic 
inﬂ  ammation and cancer (Shapiro et al. 1983; 
Kofﬂ  er et al. 1973; Leon et al. 1981). Increased 
levels of circulating DNA have also been described 
after exhaustive exercise or trauma (Atamaniuk 
et al. 2004; Lo et al. 2000). The serum of cancer 
patients is enriched in DNA containing on average 
around 4 times the amount of DNA compared to 
normal controls (Shapiro et al. 1983), although this 
is variable and overlap exists between the two 
groups. Initial studies demonstrated that higher 
levels of circulating DNA could be detected in the 
serum of patients with metastatic disease compared 
to those patients with localised disease (Leon et al. 
1977) and more recently it has been estimated that 
in Dukes stage B colorectal cancer 0.15% of 
tumour DNA is fed into the circulation each day 
increasing to over 3% in more advanced disease 
(Diehl et al. 2005). Further studies have demon-
strated a correlation between circulating DNA 
levels and prognosis in a number of tumour types 
(Maebo, 1990).
The mechanism and source of DNA release 
remains largely uncertain and a number of poten-
tial explanations have been explored including 
release of DNA from either malignant or 
haemopoietic apoptotic cells and release of DNA 
from necrotic cells.
One hypothesis is that DNA is released due to 
lysis of circulating cancer cells or micrometastases. 
It is well established that metastatic tumour cells 
can circulate in the blood however circulating DNA 
can be detected in the plasma of patients in whom 
circulating metastatic cells are not found (Castells 
et al. 1999) and where there may not be enough 
circulating cells to justify the amount of DNA 
detected (Anker et al. 1999). 
DNA released from apoptotic cells is uniformly 
digested into 185–200bp fragments (equivalent to 
whole-number multiples (1-5x) of nucleosomal 
DNA). DNA with fragment sizes typical for apop-
tosis has been demonstrated in the plasma of patients 
with systemic lupus erythrematosus and in patients 
following haemodialysis (Atamaniuk et al. 2006). 
It is suggested that the majority of this DNA is 
released from apoptotic leucocytes. In support of 
this, sex mismatched bone marrow transplantation 
patients have been used to demonstrate that the 
majority of circulating DNA in these patients comes 
from the haemopoietic system (Lui et al. 2002). The 
contribution of DNA from the haemopoetic system 
in patients with epithelial tumours is yet to be deter-
mined. One study found little contribution of T-cells 
to the bulk of plasma DNA in patients with solid 
tumours (Jahr et al. 2001).
The source of the DNA in cancer patients remains 
an ongoing area of investigation. It was not until the 
1990s following reﬁ  nement of PCR-based tech-
nologies that the neoplastic characteristics of plasma 
DNA in cancer patients were recognised. In 1994 
Sorensen and coworkers demonstrated that mutated 
K-Ras sequences could be detected by PCR in the 
plasma or serum of patients with pancreatic cancer 
(Sorenson et al. 1994) and in the same year point 
mutations in the N-Ras gene were documented in 
the plasma of patients with myelodysplastic 
syndrome (Vasioukhin et al. 1994). More recently it 
has been shown that tumour speciﬁ  c epigenetic 
alterations such as hypermethylation of promoter 
region of tumour suppressor genes can be detected 
in the plasma DNA of cancer patients (see Table 1 
for summary) conﬁ  rming that, at least in part, circu-
lating DNA is derived from the primary tumour. The 
proportion of circulating DNA that is tumour-derived 309
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Table 1. Methylation Markers in Circulating DNA from Cancer Patients.
Tumour   Sample   Methylation   Tumour   Serum or   Method  Reference
type  size  Markers  sample   Plasma    
    positive  positive   
      No  (%)   
NSCLC  22  p16  9 (41)  3 (14)  MSP  (Esteller et al. 1999)
    DAKP  5 (23)  4 (18)   
    GSTP1  2 (9)  1 (5)   
    MGMT  6 (27)  4 (18)   
NSCLC  91  MGMT  ND  17 (18)  MSP  (Fujiwara et al. 2005)
  p16   14  (15)   
  RASSF1A    11  (12)   
  DAPK    10  (11)   
  RARβ2    6  (7)   
NSCLC  35  p16  22 (63)  12 (34)  MSP  (Bearzatto et al. 2002)
NSCLC  50  RASSF1A  17 (34)  17 (34)  MSP  (Ramirez et al. 2003)
    DAPK  23 (45)  20 (40)   
    TMS1  18 (35)  17 (34)   
NSCLC  89  APC  95 (96)  42 (47)  MSP  (Usadel et al. 2002)
NSCLC  105  p16  73 (79)  77 (73)  MSP  (An et al. 2002)
NSCLC 115  14-3-3σ  ND  39 (34)  MSP  (Ramirez et al. 2005)
NSCLC  50  p16  (84)  (72)  MSP  (Liu et al. 2003)
NSCLC  61  p16  (79)  (26)  MSP  (Ulivi et al. 2006)
  CDH13  (66)  (23)  
CRC  58  p16  31 (53)  21 (40)  MSP  (Lecomte et al. 2002)
CRC  49  APC  nd  28 (57) in   Methy  (Leung et al. 2005)
    HMLH1    at least one   Light 
  HLTF    marker   
CRC  122  DAPK  67 (55)  3/14 (21)  MSP  (Yamaguchi et al. 2003)
CRC  52  p16  20 (38)  14/20 (70)  MSP  (Zou et al. 2002)
CRC  94  p16  44 (47)  13/44 (30)  MSP  (Nakayama et al. 2002)
Breast  148  RASSF1A  ND  29 (19)   Methy  (Fiegl et al. 2005)
      pre-treatment  Light 
        33 (22.3) at    
      1  year   
Breast  20  RASSF1A  ND  3 (15)  MSP  (Skvortsova et al. 2006)
  RARβ2   3  (15)   
Breast  35  p16  8 (23)  5/8   PCR +   (Silva et al. 1999)
        restriction
        enzyme   
        digest 
Breast  34  RASSF1A  22 (65)  19 (56)  MSP  (Dulaimi et al. 2004)
    APC  15 (44)  10 (29)   
    DAPK  17 (50)  12 (35)   
Ovary  50  BRCA1  12 (24)  7/43 (16)  MSP  (Ibanez de Caceres
    RASSF1A           et al. 2004)
    25  (50)  12/43  (28)   
    APC  5 (100)  4/5 (80)   
    P14  3 (100)  1/3 (33)   
    P16  5 (100)  4/4 (100)   
    DAPK  3 (100)  2/3 (67)   
(Continued)310
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Table 1. (continued)
Tumour   Sample   Methylation   Tumour   Serum or   Method  Reference
type  size  Markers  sample   Plasma    
      positive  positive   
        No  (%)   
HCC  22  p16  16 (73)  13/16  MSP  (Wong et al. 1999)
HCC  25  p15  16 (64)  4/16 (25%)  MSP  (Wong et al. 2000)
HCC  29  p16  ND  23 (80%)  Methy  (Wong et al. 2003)
          Light 
Renal   26  APC  5/17 (29)  1/18 (6)  Quantitative  (Hoque et al. 2004)
cell      ARF  4/17 (25)  1/18 (6)  real time  
cancer     CDH1  10/17(59)  6/18  (33)  PCR 
    GSTP1  2/17  (12)  1/18  (6)   
    MGMT  1/17  (6)  0/18  (0)   
    P16 6/17  (35)  4/18  (22)   
    RAR-B2  9/17  (53)  1/18  (6)   
    RASSF1A  15/17  (88)  2/18  (11)   
    TIMP3  12/17  (71)  3/18  (17)   
Head and   95  P16  26 (27)  8/26 (31)  MSP  (Sanchez-Ces
neck     MGMT  31 (33)  14/29 (48)     pedes et al. 2000)
    DAPK  17  (18)  3/17  (18)   
    GSTP1  0/41  (0)     
Gastric  54  E-cadherin  41 (75)  31/41 (57)  MSP  (Lee et al. 2002)
    P16 36  (67)  28/36  (52)   
    P15 37  (68)  30/37  (56)   
    DAPK  38  (70)  26/38  (48)   
    GSTP1  10  (18)  8/10  (56)   
Oeso-  52  APC  48 (92)  13 (25)  MSP  (Kawakami et al.
phageal              2000)
Bladder  27  p14  15 (56)  13/15  MSP  (Dominguez et al.
    p16 5  (18)  2/5    2002)
Melanoma  50  RASSF1A  9/18 (50)  13 (26)  MSP  (Mori et al. 2005)
    RAR β2 11/18(61)  10  (20)  
    MGMT  2/18  (11)  5  (10)   
Melanoma  107/109  ER-alpha  55/107 (51)  26/109 (24)  MSP   (Mori et al. 2006)
Prostate  33  GSTP1  16/17 (90)  23/ 32 (72)  MSP   (Goessl et al. 2000)
Prostate  85   GSTP1  ND  10 (12)  Restriction   (Bastian et al. 2005)
  (localised       5 (28)  endonuclease 
 disease)        PCR
 18
 (HRPCa)
Abbreviations: CRC, colorectal cancer; NSCLC, non small cell lung cancer; HCC, hepatocellular cancer; RASSF1A, Ras-association 
domain family 1A; GSTP1, glutathione S-transferase P1; RARβ2￿ , retinoic acid receptor β2; DAKP, death associated protein kinase; 
MGMT, 0–6 methylguanine DNA methyltransferase; ER, oestrogen receptor; APC, adenomatous polyposis coli; MSP, methylation speciﬁ  c 
PCR; ND, not done; HRPCa, hormone refractory prostate cancer.311
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varies amongst studies from less than 3% to more 
than 90% (Jahr et al. 2001) and from 0.02% to 8–11% 
(Diehl et al. 2005). It is not yet known whether these 
differences result from the different methodologies 
used or whether they reﬂ  ect distinct biological behav-
iour in different tumours types. 
It has been proposed that as tumours enlarge there 
is hypoxia-induced necrosis of both the tumour cells 
and surrounding stroma and inﬂ  ammatory cells (Jahr 
et al. 2001). These cells may be phagocytosed with 
subsequent release of DNA into the circulation 
containing both tumour specific and wild type 
sequences. Diehl et al. 2005 demonstrated that the 
majority of mutated APC sequences in patients with 
colorectal cancer were detected in the smaller size 
fragments of circulating DNA, whereas larger frag-
ments tended to be wild-type.
Jahr and co-workers observed an increase in 
total DNA concentration following either apoptosis 
(CD95) or necrosis (acetaminophen) induced liver 
damage in mice. DNA of a higher molecular weight 
was observed following induction of necrosis alone 
(Jahr et al. 2001). This suggests that the DNA in 
cancer patients comes from both an apoptotic and 
necrotic source and that the higher molecular 
weight fragments originate from cell necrosis. In 
contrast to DNA extracted from healthy individuals, 
DNA from cancer patients has a different pattern 
of fragment sizes. It has been demonstrated that 
the integrity of DNA extracted from serum or 
plasma is signiﬁ  cantly increased in patients with 
colorectal, gynaecological and breast cancer 
compared to normal controls (Umetani et al. 2006; 
Wang et al. 2003). Further studies are planned to 
investigate whether elevated levels of longer DNA 
fragments in blood may provide a useful biomarker 
in the management of cancer.
The clearance mechanism of circulating DNA 
is not yet known and it is not clear whether differ-
ences exist between healthy individuals and cancer 
patients. It has been demonstrated that patients with 
stomach and colorectal cancer have lower levels 
of DNAse activity compared with controls 
(Skvortsova et al. 2006). The half-life of DNA 
extracted from haemodialysis patients was deter-
mined to be approximately 4 minutes (Rumore 
et al. 1992) and the half life of circulating foetal 
DNA in the maternal system is 16 minutes (Lo 
et al. 1999). To date no studies have investigated 
the half-life of circulating DNA in cancer patients. 
The role of hepatic and renal clearance has also 
not been investigated in detail although it has been 
demonstrated that mutated DNA sequences can be 
detected in the urine of colorectal and pancreatic 
cancer patients suggesting renal excretion as one 
potential clearance mechanism (Su et al. 2004).
Despite the uncertainties surrounding the precise 
source and role of circulating DNA, many studies 
have now demonstrated the presence of tumour-
speciﬁ  c changes in circulating DNA providing the 
opportunity to develop blood borne biomarkers for 
cancer. One such change is the methylation of the 
promoter regions of tumour suppressor genes.
DNA methylation
Classically, cancer has been thought of as a disease 
driven by genetic abnormalities including mutations 
in tumour suppressor genes and oncogenes. 
However, more recently it has become apparent that 
epigenetic alterations also play a role in cancer 
progression and its maintenance. The term 
“epigenetic” refers to altered patterns of gene 
expression mediated by changes other than an 
alteration in the primary nucleotide sequence. One 
such epigenetic change is abnormal DNA methyla-
tion. In the mammalian genome methylation takes 
place primarily at cytosine bases. Methylation is 
catalyzed by DNA methyltransferase enzymes that 
use s-adenosyl-methionine as a methyl donor to 
replace a hydrogen atom with a methyl group at the 
carbon 5 position of the cytosine pyrimidine ring 
(Ramsahoye et al. 2000). This only occurs at cyto-
sine bases located 5′ to a guanosine in a CpG 
dinucleotide (Herman and Baylin, 2003). Meth-
ylation of CpG sites within promoter regions is an 
important mechanism for controlling gene expres-
sion in normal cells (Klose and Bird, 2006). There 
are three main mechanisms which link methylation 
to cancer: transcriptional silencing via hypermeth-
ylation in the promoter regions of tumour suppressor 
genes, hypomethylation (demethylation) resulting 
in the failure to repress expression of tissue restricted 
or proto-oncogenes and genome wide hypomethyl-
ation leading to increased mutation rates and chro-
mosome instability (Feinberg et al. 2002). CpG 
dinucleotides occur throughout the genome but are 
clustered in short regions of 0.5–4kb in length, 
known as CpG islands (Bird, 2002). Most CpG 
islands are located at the promoter regions of genes 
and are unmethylated in normal cells. Hypermeth-
ylation of these regions causes altered transcription 
or “silencing” of the target gene. This may be a 
natural event, for example fully methylated islands 312
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are associated with many silent genes on the inactive 
X chromosome in females. However, it is now 
recognised that the epigenetic programme of human 
tumours is frequently abnormal leading to adverse 
transcriptional proﬁ  les and increased genetic insta-
bility (Robertson, 2005). Loss of methylation may 
affect the stability of chromosomal structure as 
demonstrated among patients with the rare immu-
nodeficiency centromeric instability and facial 
abnormalities syndrome (ICF, MIM#242860). 
These patients have failure to thrive, recurrent infec-
tion and variable mental retardation due to reduced 
levels of DNA methyltransferase 3B, which results 
in loss of methylation at selected centromeric 
regions and marked alterations in chromosomal 
structure (Esteller et al. 2000).
Epigenetic modiﬁ  cation may be a more frequent 
cause of loss of function than genetic defects (Jones 
and Baylin, 2002). Promotor hypermethylation has 
been observed at well characterised tumour suppressor 
gene sites that can cause cancer when mutated in the 
germ line such as BRCA1 (Esteller et al. 2000) and 
VHL (Herman et al. 1994). A number of candidate 
tumour suppressor genes have been identiﬁ  ed on the 
basis of promoter hypermethylation in different cancer 
types (Esteller, 2007). Promoter methylation may be 
the only cause of the reduced expression of these genes 
in cancer with mutations less frequently observed.
Detection of DNA methylation
Three different needs in the ﬁ  eld of methylation 
analysis have been identiﬁ  ed; genome wide estima-
tion of DNA methylation, quantitative methylation 
measurements (detection down to 5% methylated 
DNA) and ultra sensitive quantiﬁ  cation (detection 
down to 1% methylated DNA). A number of 
reviews have been published detailing the plethora 
of methods available (Laird, 2003; Brena et al. 
2006) but, as methylation analysis is an emerging 
ﬁ  eld, new detection methods are regularly released 
to the research community. With this in mind a 
detailed description of all available methodologies 
is outside the scope of this review. Brieﬂ  y, the 
majority of methods require three main steps:
1.  An initial step to differentiate between methyl-
ated and non methylated DNA in order to make 
this difference analyzable. Methods most com-
monly used are:
 a.  Bisulﬁ  te conversion of genomic DNA    
  (Frommer et al. 1992). 
    Here, methylation is not retained during  
 the  ampliﬁ  cation process of PCR, a step  
  which is required by several methylation  
  assays. Treatment of DNA with sodium  
 bisulﬁ  te allows conversion of genomic  
  DNA, retaining the methylation pattern.  
  Unmethylated cytosines are deaminated  
  to uracil by sodium bisulﬁ  te and methyl- 
  ated cytosines are resistant to modiﬁ  ca- 
  tion and remain as cytosine
  b. Physical separation using DNA binding  
  proteins with high speciﬁ  city for methyl- 
 ated  DNA
  or
  c.  Endonuclease digestion 
    Here, isoschizomers of bacterial restric - 
  tion enzymes with different sensitivities  
  for 5-methylcytosine will preferentially  
  cut either methylated or non-methylated  
  DNA. However, this is limited by the    
  fact that this will only inform on the    
  methylation status of the cytosine resi-  
  dues recognized by the methylation-sensi- 
  tive restriction enzymes used.
2. Many analysis applications require an 
ampliﬁ  cation step, usually by PCR, to enable 
methylation detection. There are a number of 
options depending on primer design. In simple 
terms the PCR can be methylation specific 
(MSP) or independent.
  MSP, the most widely used method of DNA 
methylation analysis, uses primers that bind 
specifically to methylated or non-methylated 
DNA. This is an ultra sensitive method of 
detection commonly used for the detection 
of very few molecules of methylated DNA 
in an excess of non-methylated DNA (sensi-
tivity reported as 1:1000) (Herman et al. 
1996).
  Methylation independent PCR is achieved by 
excluding any CpG site form the primer hybrid-
ization sites, commonly used for the quantitative 
detection of DNA methylation in the range of 
5% to 95% percent methylated DNA. Whilst 
not as sensitive as MSP, this method is useful 
for the quantitative or detailed analysis of 
5-methylcytosine distribution.
3. Following ampliﬁ  cation a number of detection 
methods are available to analyze the results. The 
most common include capillary sequencing, 
pyrosequencing, mass spectrometry, gel 
electrophoresis and RT-PCR.313
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Many publications assessing methylation in 
patients with cancer have used conventional MSP 
ampliﬁ  cation with gel electrophoresis readout. 
This is an ultra sensitive method of analysis and 
due to its simplicity it is widely used in its ﬁ  eld. 
However, MSP detects only the presence or 
absence of methylated alleles in a “yes or no” 
fashion and is not quantitative. Furthermore, 
unless DNA is also ampliﬁ  ed with wild type 
primers speciﬁ  c for unmodiﬁ  ed DNA, there is no 
control for adequacy of bisulphite treatment 
which may lead to false positives if non methyl-
ated cytosines have been inadequately converted 
to uracil. There is also potential for mis-priming 
especially with high numbers of PCR cycles 
(Shaw et al. 2006). 
A large number of techniques are available for 
quantitative analysis (Brena et al. 2006) including 
bisulﬁ  te sequencing from clones, pyrosequencing 
(Tost et al. 2003; Colella et al. 2003) or mass spec-
trometry in combination with methylation inde-
pendent PCR as well as a number of quantitative 
PCR methods based on the detection of methylated 
sequences via ﬂ  uorescence in the PCR reaction, e.g. 
MethyLight (Eads et al. 2000), HeavyMethyl and 
quantitative analysis of methylated alleles (QAMA) 
(Zeschnigk et al. 2004). These have individual 
advantages and disadvantages, mainly related to the 
concentration of DNA required for analysis and the 
sensitivity of the test.
Many of the techniques described above are 
suitable for analysis of DNA methylation in a 
speciﬁ  c gene promoter. A number of assays are 
also available for the measurement of genome wide 
methylation using techniques such as high-
performance liquid chromatography (HPLC) or 
high performance capillary electrophoresis 
(HPCE). It is also possible to detect DNA meth-
ylation in discrete areas of the genome such as CpG 
islands with restriction landmark genomic scan-
ning (RLGS) or bacterial artiﬁ  cial chromosome 
(BAC) arrays. Furthermore, novel technologies 
that make use of CpG island and promoter micro-
arrays can efficiently study methylation at a 
genome wide level. These techniques are less suit-
able for development of biomarkers due to the large 
quantities of DNA required, but they have been 
successfully employed to monitor global changes 
in methylation and to discover novel tumour 
suppressor genes. 
It should be emphasized that generally no single 
technique or general approach is superior to the 
others. The method of choice will depend on the 
desired application and the goals of the study 
planned.
Hypermethylation in plasma
and serum
Promotor methylation has been reported in a number 
of different genes across a range of tumour types 
(Rodenhiser and Mann, 2006). Some genes are 
methylated in a number of cancers whereas others 
appear more speciﬁ  c for certain tumour types. The 
ﬁ  rst studies to show it was possible to detect meth-
ylation changes in serum DNA from cancer patients 
were reported by Esteller and co-workers (Esteller 
et al. 1999) in 1999 in NSCLC patients and by Wong 
and co-workers (Wong et al. 1999) who demon-
strated p16 methylation in plasma and serum of 
patients with liver cancer. Subsequently a number 
of studies have evaluated the potential of circulating 
tumour DNA methylation in serum and plasma for 
the molecular diagnosis and/or prognosis of a variety 
of cancer types. The most extensively studied are 
summarised in the table below. 
In general there is concordance between the 
methylation changes in plasma or serum and those 
changes in the primary tumour. Most often if DNA 
methylation is detected in the serum or plasma 
then the primary tumour will also be positive for 
the same alteration (Skvortsova et al. 2006; 
Esteller et al. 1999; Wong et al. 1999; Bearzatto 
et al. 2002; Ramirez et al. 2003; Zou et al. 2002; 
Fiegl et al. 2005; Dulaimi et al. 2004). However, 
exceptions to this have been reported in small 
numbers of cases (Fujiwara et al. 2005). The 
reasons for the presence of methylation in the 
blood when it is absent in the primary tumour are 
not clear. This may simply be due to a heteroge-
nous clonal malignant population such that arbi-
trary tumour sampling failed to biopsy regions of 
methylation.
DNA methylation in normal tissue
An important measure of an effective biomarker 
assay is the sensitivity and speciﬁ  city of the test. 
Sensitivity refers to the proportion of cases with 
disease that test positive i.e. true positives, and 
speciﬁ  city refers to the number of control cases 
(people without disease) who test negative i.e. true 
negatives. If methylation markers can be identiﬁ  ed 
in tumours which are absent in normal cells then 
this may yield an important potential screening 314
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tool. DNA methylation changes have been reported 
to occur early in the carcinogenic process and are 
potentially good indicators of early disease (Laird, 
2003). Molecular analysis on tumour adjacent 
‘normal tissue’ has detected a number of genetic 
alterations including methylation. (Hoque et al. 
2006; Shen et al. 2005). The reasons for methyla-
tion in the apparent absence of disease are as yet 
not well deﬁ  ned but there may be a number of 
explanations. 
1. These alterations may be explained by the con-
cept of ﬁ  eld cancerization (or ﬁ  eld defect); a 
term originally used to describe the discovery 
of histologically abnormal epithelium surround-
ing oral cancers (Slaughter et al. 1953). As it 
has become increasingly established that an 
accumulation of genetic alterations takes place 
transforming a normal cell to a cancer cell 
(multi-step carcinogenesis, (Fearon and 
Vogelstein, 1990)) a molecular basis for ﬁ  eld 
cancerization can be described. It is hypothe-
sised that a stem cell acquires a genetic altera-
tion and forms a patch with identical daughter 
cells. The lesion gradually becomes a ﬁ  eld, 
laterally displacing the normal epithelium. As 
the lesion becomes larger additional genetic hits 
give rise to various subclones, one (or more) of 
which may develop into an invasive cancer 
(Braakhuis et al. 2003). Hence histologically 
‘normal’ epithelium adjacent to a cancer may 
harbour cancer associated genetic changes.
2. Methylation may be a consequence of environ-
mental exposure to a carcinogen such as tobacco 
or another as yet unidentiﬁ  ed compound. DNA 
methylation changes are more common in prostate 
and lung cancer tissue of smokers (Enokida et al. 
2006; Liu et al. 2006). In a study of lung cancer 
survivors, never smokers and cancer free smokers, 
DNA methylation was more common in smokers 
than in non smokers (Belinsky et al. 2005). 
3. Methylation has been shown to increase with 
increasing age in colorectal mucosa (Issa et al. 
1994; Ahuja et al. 1998). Extensive evaluation 
of methylation changes in normal tissue needs 
to be undertaken before one can be certain of 
the speciﬁ  city of any assays.
  Whilst DNA methylation in normal tissue may 
make discriminatory assays less sensitive, in 
those studies of circulating DNA that include 
disease free populations as control cases, the 
specificity of DNA methylation has been 
remarkably high (Bearzatto et al. 2002; Usadel 
et al. 2002; Zou et al. 2002; Dulaimi et al. 2004; 
Wong et al. 2000; Lee et al. 2002; Goessl et al. 
2000). In these trials, promotor methylation of 
the target genes has only been detected in the 
serum or plasma of those patients with cancer 
and not control subjects. However, more recently 
in a study reported by Hoque and coworkers 
(Hoque et al. 2006), the frequency of methyla-
tion of four genes (APC, GSTP1, RASSF1A and 
RARβ2) was determined in the plasma of breast 
cancer patients using quantitative MSP. Meth-
ylation of at least one gene resulted in a sensitiv-
ity of 62% and a speciﬁ  city of 87%. Methylation 
was detected in the plasma of 13% of control 
subjects which may be explained by the more 
sensitive detection methods used in this study.
DNA methylation as a prognostic 
and predictive biomarker
DNA methylation has been investigated as a poten-
tial prognostic and predictive biomarker (Table 2). 
The presence of tumour specific methylation 
markers in the serum or plasma has been reported 
to be of prognostic signiﬁ  cance in a number of 
tumour types which supports a role for methylation 
in cancer progression.
Other types of clinical sample
for extraction of DNA
DNA methylation has been detected in a number 
of bodily fluids of patients with cancer, for 
example urine, saliva and ascitic fluid. In some 
tumour types this may be an alternative to tissue 
biopsy and like blood samples may provide a 
less invasive approach to the monitoring of 
biomarkers compared to tissue sampling. 
Cancers of the bladder, kidney and prostate 
contribute cellular DNA to urinary sediment 
(Perry et al. 2006) and this DNA can be analysed 
for panels of methylation markers. Promotor 
methylation of the GSTP1 gene has been 
detected in the urine and ejaculates of men with 
prostate cancer but not in patients with benign 
prostatic hyperplasia (Goessl et al. 2000). A 
combination of four genes (p16, ARF, MGMT, 
and GSTP1) has been proposed to detect pros-
tate cancer with an estimated 87% sensitivity 
and 100% specificity (Hoque et al. 2005). 315
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In lung cancer, DNA methylation changes can 
be detected in the sputum of patients (Machida 
et al. 2006). It has been suggested that this may 
also play a role in early detection and assessment 
of lung cancer risk. Methylation of the p16 and 
MGMT promotor regions has been detected in the 
sputum up to 3 years prior to the diagnosis of 
squamous cell carcinoma (Palmisano et al. 2000) 
and more recently panels of genes have been 
evaluated as possible markers for early lung cancer 
detection with a sensitivity and speciﬁ  city of 65% 
(Belinsky et al. 2006). 
Methylated genes have been detected in 
peritoneal and ascitic ﬂ  uid of patients with ovarian 
cancer (Ibanez de Caceres et al. 2004; Muller et al. 
2004). One study demonstrated that methylation 
was speciﬁ  c for patients with cancer with no meth-
ylation detected in any of the genes in peritoneal 
ﬂ  uid from patients with benign ovarian disease 
(Ibanez de Caceres et al. 2004).
In breast cancer, methylation of genes can be 
detected in cancer cells collected by ductal 
lavage (Evron et al. 2001) and in nipple aspirate 
fluid (Krassenstein et al. 2004). And, in head 
and neck cancers, methylation of p16, DAPK 
and MGMT have been detected in saliva (Rosas 
et al. 2001).
Development of a panel of markers
In order to increase the sensitivity and speciﬁ  city of 
genetic and epigenetic biomarkers many combina-
tions and panels of genes have been investigated to 
see if a combination of markers will improve sensi-
tivity and specificity of assays. Many studies 
combine a number of methylated genes to try and 
identify a panel of markers which are more speciﬁ  c 
than a single change on its own. New technologies 
such as gene arrays have been adapted to screen 
hundreds of promotor regions to yield a more 
speciﬁ  c “signature” or methylation phenotype for 
cancer versus normal tissue. Multiple methylation 
events often termed the CpG island methylator 
phenotype (CIMP) have been described in a number 
of cancers, most extensively in colorectal cancers.
Colorectal cancer is associated with a number 
of genetic and epigenetic alterations. One of the 
most important is the presence of multiple micro-
satellite repeats, short repetitive DNA sequence 
tracts, termed microsatellite instability (MSI). MSI 
is also found in about 15% of sporadic CRCs and 
is usually the result of acquired loss of the 
mismatch repair gene hMLH1 (Thibodeau et al. 
1993). Studies of methylation in colon cancer 
revealed increased frequencies of promoter 
methylation in the mismatch repair gene MLH1 in 
Table 2. DNA methylation as a Prognostic and Predictive Biomarker.
Tumour Type  Marker  Signiﬁ  cance  Reference
Oesophageal  APC  Reduced survival (with high   (Kawakami et al. 2000)
    levels of methylation) 
Breast  RASSF1A  Independent prognostic   (Muller et al. 2003)
 APC  markers 
    RR death 5.7 
Breast  RASSF1A  Persistence of plasma   (Muller et al. 2003)
    RASSF1A after 1 year of  
    therapy associated with poor  
   outcome   
NSCLC 14-3-3σ  Longer survival in patients  (Ramirez et al. 2005)
    treated with cisplatin and  
   gemcitabine  chemotherapy 
NSCLC  APC  High APC methylation   (Usadel et al. 2002)
    associated with poor survival 
Melanoma  RASSF1A  Worse overall survival with   (Mori et al. 2005)
 RAR β2  at least 1 methylated gene.  
    Methylated RASSF1A  
   correlated  with 
    biochemotherapy response  
Prostate  GSTP1  Predicts for PSA recurrence   (Bastian et al. 2005)
    following prostatectomy  HR 4.4 316
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MSI-positive tumours suggesting that hypermeth-
ylation leads to MSI through silencing of MLH1. 
Subsequently a number of studies have added to 
the list of genes preferentially hypermethylated in 
sporadic MSI-positive cases of colorectal cancer 
including p16, TIMP and MINTS –1, –2 and –31 
(Whitehall et al. 2002; Hawkins et al. 2002; Toyota 
et al. 2000). Further research has demonstrated that 
CIMP positive cancers represent a unique subset 
of tumours. They are more common in older 
patients, proximal colon cancers and in women and 
are also associated with distinct genetic alterations 
and high mutation rates in the KRAS and BRAF 
genes (Issa, 2004).
Similar distinct subsets of cancer based on 
tumour hypermethylation have been described 
(Esteller et al. 2001) in a number of other tumours 
including ovarian (Wei et al. 2006), gastric (Toyota 
et al. 1999) and pancreatic cancers (Ueki et al. 
2000). Further study will determine which panels 
of genes are most effective as biomarkers for 
population screening, prediction of response to 
therapy and prognosis. Much more work is 
required on methylation detection in circulating 
DNA to develop these tests into clinically 
applicable resources.
The different methylation patterns detected in the 
same histologically deﬁ  ned group of cancers may 
indicated important differences in tumorigenesis and 
may help identify subsets of patients which differing 
molecular characteristics in the tumour which confer 
a particular clinical behaviour. Methylation status 
analysis may further both our understanding of the 
pathogenesis of cancer and may provide useful tools 
in the move to “personalised” treatment for cancer 
based on particular molecular change.
Conclusions
Increasing knowledge of epigenetic alterations in 
cancer has provided unprecedented opportunity to 
evaluate the use of these changes as potential 
biomarkers in cancer. It is becoming increasingly 
apparent that these alterations can be detected in 
the blood of patients with cancer, highlighting 
potential for application in routine clinical practice. 
Already a number of potential markers or panels 
of markers have been identiﬁ  ed in the plasma of 
patients with a number of cancers. If aberrant DNA 
methylation can be detected in the plasma this 
could have a potential use as an early indicator of 
disease in an asymptommatic population or as a 
predictive or prognostic test in the case of known 
disease. However, there are several caveats to the 
use of blood-borne biomarkers as surrogates for 
tumour biomarkers. Whilst positive plasma or 
serum assays are often only found in those patients 
with positive assays in the primary tumour, a 
proportion of patients will not have detectable 
alterations in the blood despite harbouring changes 
in the primary tumour. Many questions remain 
unanswered. Is a negative result is due to a real 
absence of methylated sequences?. Or are such 
sequences present, but at a level not detectable by 
current tests? Is the presence or absence of methyl-
ated sequences related to the size or vascularity of 
the primary tumour? Have these sequences been 
already cleared from the circulation?
With continued improvements in technology 
and increasing sensitivity of detection methods our 
understanding of the precise role of many of these 
changes will become clearer. Further work is 
required to reﬁ  ne, standardise and validate the 
extraction of DNA from plasma and the analytical 
methods use to measure and quantify genetic 
change. The incorporation of the study of 
biomarkers alongside traditional phase I, II and III 
clinical trials will further enhance our knowledge 
of the relevance of these changes to help guide 
treatment and target those patients most likely to 
beneﬁ  t from speciﬁ  c therapies. 
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